BPC-157 vs LL-37
BPC-157 (Synthetic pentadecapeptide) and LL-37 (Cathelicidin antimicrobial peptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | BPC-157 | LL-37 |
|---|---|---|
| Compound class | Synthetic pentadecapeptide | Cathelicidin antimicrobial peptide |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | 15 amino acids | 37 amino acids |
| Molecular weight | 1419.5 Da | ~4493 Da |
| Half-life | <30 minutes (elimination, reported in rats/dogs) | Not documented |
| Origin | BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research. | LL-37 is a naturally occurring human antimicrobial peptide, the active fragment released from the C-terminal region of the human cathelicidin precursor protein hCAP18. It is part of the innate immune system and is expressed by neutrophils and various epithelial cells. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How BPC-157 works
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
How LL-37 works
LL-37 is a cationic, amphipathic host-defense peptide that can disrupt microbial membranes, giving it broad antimicrobial activity. Beyond direct killing, it has immunomodulatory roles, including chemotactic effects on immune cells, modulation of inflammatory signaling, and reported influence on angiogenesis and wound healing. These roles are documented in in-vitro and animal studies as part of innate immunity.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
BPC-157
LL-37
What sets each apart
BPC-157
Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.
LL-37
LL-37 is unique in this group as a natural host-defense peptide combining direct antimicrobial activity with immune modulation, rather than being a synthetic repair-focused peptide.
Frequently asked questions
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
What is BPC-157 studied for in the research literature?
In animal models, BPC-157 has been researched in the context of tendon, ligament, muscle, and bone healing, gastrointestinal mucosal protection, and angiogenesis. Much of the work implicates nitric oxide pathways and upregulation of growth-factor and angiogenic signaling. To date these findings are almost entirely preclinical, and no human clinical efficacy has been established.
Why is BPC-157's short half-life not reflected in dosing frequency?
Pharmacokinetic work in rats and dogs reports an elimination half-life under about 30 minutes, yet most rodent studies use once-daily dosing. This is often described as a PK/PD disconnect: the downstream biological effects the peptide triggers persist well beyond the peptide's own residence time. Researchers therefore design protocols around effect duration rather than plasma half-life.
What is LL-37?
LL-37 is the sole human cathelicidin antimicrobial peptide, a 37-amino-acid amphipathic alpha-helical peptide released from the C-terminal region of the hCAP18 precursor. It is named for its two leading leucine residues and its length. It functions in the innate immune system as a first-line defense at sites of infection, inflammation, and wounds.
What is LL-37 studied for?
Research examines LL-37 for direct antimicrobial activity against bacteria, and for antiviral, immunomodulatory, angiogenic, and wound-healing roles. Multiple patents describe LL-37 and its derivatives for wound healing. It is also studied in the context of inflammatory and autoimmune conditions, where it can present nucleic acids to immune receptors.
How does LL-37 kill microbes?
As a cationic, amphipathic alpha-helix, LL-37 interacts with and disrupts negatively charged microbial membranes, permeabilizing them. This membrane-targeting mechanism makes broad resistance harder to develop than with conventional antibiotics, which is a key reason it is studied as an antimicrobial-peptide template.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.